Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Status:
Recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

This is a phase IV, single-center, prospective, open-label, randomized,controlled study

Phase 4

Tao OUYANG

Hormones
Mitogens
Vinorelbine